Abstract
Several reports indicated that aberrant miR-1826 was involved in the initiation and progression of malignancies. However, the clinical significance of miR-1826 in human colorectal cancer (CRC) has not been addressed. The aim of this study was to evaluate the expression and clinical significance of miR-1826 in CRC. We detected miR-1826 expressions by quantitative realtime PCR (qRT-PCR) in 72 CRC tissues, adjacent nontumor tissues (NATs) and five CRC cell lines, and found that miR-1826 expression in CRC tissues was higher than that in NATs (p<0.05). High miR-1826 expression was significantly associated with some clinicopathologic features such as regional lymph node metastasis (p=0.018), advanced TNM clinical stage (p=0.004), which led to a poor overall survival rate in CRC patients (p=0.032). Our further studies in vitro also demonstrated that miR-1826 inhibitor could effectively suppress the cell proliferation, promote apoptosis and induce G0/G1 cell cycle arrest in CRC cells (p<0.05). Meanwhile, the abilities of cell invasion and migration were effectively suppressed by miR-1826 inhibitor (p<0.05). These findings strongly suggested that miR-1826 played a critical role in the initiation and progression of CRC. Up-regulation of miR-1826 might serve as a novel prognostic marker of CRC and could be a potential target for CRC therapies.
Keywords: Biomarker, colorectal cancer, miR-1826, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Volume: 16 Issue: 9
Author(s): You Hu, Bin Yi, Songbing He, Ling Gao, Pengfei Liu, Lei Wang, Jing Yu, Daiwei Wan, Jin Zhou, Xinguo Zhu and Qiaoming Zhi
Affiliation:
Keywords: Biomarker, colorectal cancer, miR-1826, prognosis.
Abstract: Several reports indicated that aberrant miR-1826 was involved in the initiation and progression of malignancies. However, the clinical significance of miR-1826 in human colorectal cancer (CRC) has not been addressed. The aim of this study was to evaluate the expression and clinical significance of miR-1826 in CRC. We detected miR-1826 expressions by quantitative realtime PCR (qRT-PCR) in 72 CRC tissues, adjacent nontumor tissues (NATs) and five CRC cell lines, and found that miR-1826 expression in CRC tissues was higher than that in NATs (p<0.05). High miR-1826 expression was significantly associated with some clinicopathologic features such as regional lymph node metastasis (p=0.018), advanced TNM clinical stage (p=0.004), which led to a poor overall survival rate in CRC patients (p=0.032). Our further studies in vitro also demonstrated that miR-1826 inhibitor could effectively suppress the cell proliferation, promote apoptosis and induce G0/G1 cell cycle arrest in CRC cells (p<0.05). Meanwhile, the abilities of cell invasion and migration were effectively suppressed by miR-1826 inhibitor (p<0.05). These findings strongly suggested that miR-1826 played a critical role in the initiation and progression of CRC. Up-regulation of miR-1826 might serve as a novel prognostic marker of CRC and could be a potential target for CRC therapies.
Export Options
About this article
Cite this article as:
Hu You, Yi Bin, He Songbing, Gao Ling, Liu Pengfei, Wang Lei, Yu Jing, Wan Daiwei, Zhou Jin, Zhu Xinguo and Zhi Qiaoming, Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1871520615666150507122434
DOI https://dx.doi.org/10.2174/1871520615666150507122434 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Application of Electroporation in DNA Vaccination Protocols
Current Gene Therapy Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
Current Pharmaceutical Design 18 F-FDG PET/MRI of Primary Hepatic Malignancies: Differential Diagnosis and Histologic Grading
Current Medical Imaging Evaluation of Antidiabetic Activity of <i>Rosmarinus officinalis var. prostratus</i> Growing in Syria in Alloxan Diabetic Rats
Current Bioactive Compounds Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) Imaging Changes in Liver After Chemotherapy for Colon Cancer: A Case Report
Current Medical Imaging Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry